Trials / Active Not Recruiting
Active Not RecruitingNCT06240351
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
A Pilot Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- Female
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib 4 MG Oral Tablet | Baricitinib is a Janus kinase (JAK) inhibitor |
Timeline
- Start date
- 2024-04-22
- Primary completion
- 2026-07-31
- Completion
- 2027-07-31
- First posted
- 2024-02-05
- Last updated
- 2026-01-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06240351. Inclusion in this directory is not an endorsement.